This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
Industry News
News from pharmaceutical companies and other related healthcare organizations
A new drug for Cushing’s: Learn more
April 22, 2020
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
Exciting news for acromegaly and NET’s from Crinetics Pharmaceuticals!
April 9, 2020
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
News on Signifor, Signifor LAR, and newly approved Cushing’s drug ISTURISA
April 8, 2020
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
Questions about access to therapies, financial assistance?
March 30, 2020
If you are currently taking, or are about to start taking Lanreotide (Somatuline Depot) injections, this website from Ipsen offers a wealth of information about patient access to therapies. IPSEN CARES serves as a central